上海“新优药械”产品目录已纳入7批220个产品

Core Insights - The total sales of designated medical institutions in Shanghai are expected to double annually from 2022 to 2025, based on health insurance statistics for 148 queryable products [1] Group 1: Innovation in Pharmaceuticals and Medical Devices - The "New and Excellent Drugs and Medical Devices" product directory in Shanghai has seen significant growth, with 220 products selected across seven batches, including 70 drugs and 150 medical devices [3] - In 2025, Shanghai is projected to approve nine Class 1 new drugs, ranking second nationally with a share of 13.85%, and nine Class 3 innovative medical devices, ranking fourth with a share of 14.75% [2] - The implementation of the product directory has led to a notable increase in sales for included products, with the first year of inclusion showing sales increases of up to nine times [3] Group 2: Policy Support and Market Access - Shanghai has introduced several policies, including the "Several Opinions on Supporting the Innovative Development of the Biopharmaceutical Industry," to facilitate the efficient entry and application of innovative drugs [2] - The directory aims to continuously update the list of "New and Excellent Drugs and Medical Devices" and encourages hospitals to initiate procurement within one month of inclusion [2] - The directory has also supported the demonstration application and promotion of innovative products, as well as collaborations between medical enterprises for real-world efficacy evaluations [2] Group 3: Case Studies of Innovative Products - The drug "Eisupaglutide A Injection" was included in the directory in March 2025 and has been adopted by over 50 medical institutions in Shanghai, being the only domestic long-acting GLP-1 drug included in the national basic medical insurance directory [3] - The "Irinotecan Liposome Injection" has filled a gap in second-line treatment for pancreatic cancer and has seen a price reduction of 60%, significantly lowering patient costs [3] - The "Pianpili Monoclonal Antibody Injection," included in the directory last year, achieved sales of approximately 14 million yuan in 2025 across 36 medical institutions in Shanghai [3]